GoldenGolden
Advanced Search
BioVentures Investors

BioVentures Investors

A private equity and venture capital firm in Massachusetts that focuses on commercial development of advanced technology in life sciences and healthcare.

Bioventures Investors is a private equity and venture capital firm in Massachusetts that focuses on commercial development of advanced technology in life sciences and healthcare. Founded 1998 in Wellesley, Massachusetts, United States by Marc Goldberg, it invests in early stage ventures and late stage ventures. Its portfolio companies include Sonomotion, Kanova, Endotronix, POC Medical Systems, Nano-Micro Technology, Cylene Pharmaceuticals, Claros Diagnostics, Hydra Biosciences, and Biolex Therapeutics. As of March 2020, Bioventures Investors has made 32 investments. Their most recent investment was on November 12, 2019, when Sonomotion raised $10M. Bioventures Investors has had seven exits, the most notable of which include Enanta Pharmaceuticals, Phase Forward, and Spirus Medical. The company has raised a single venture fund, BioVentures Investors IV. This fund was announced on October 10, 2016 and raised a total of $87M.

Timeline

People

Name
Role
LinkedIn

James Lousararian, JD

MANAGING DIRECTOR

Jeffrey Barnes, MS, MBA

MANAGING DIRECTOR

Jonathan P. Gertler, MD

MANAGING DIRECTOR – MEDTECH GROWTH CAPITAL FUND

Marc Goldberg, JD, MBA

CO-FOUNDER AND MANAGING PARTNER

Tony Lyons

GENERAL PARTNER – MEDTECH GROWTH CAPITAL FUND

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

Biolex Therapeutics

Claros Diagnostics

Cylene Pharmaceuticals

Endotronix

Endotronix

Hydra Biosciences

Kanova

Nano-Micro Technology

POC Medical Systems

Sonomotion

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.